AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9258576
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion (3% saline solution administered on an early follicular and a late luteal phase day)
Trial: 3638441
Drug: Family-based health
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-based health behavior change intervention, 12 weekly sessions and six maintenance sessions over nine months.
Trial: 20463094
Drug: Two tablets/week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two tablets/week increase in l-T(4)
Trial: 20463094
Drug: Three tablets/week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three tablets/week increase in l-T(4)
Trial: 18166547
Drug: Guanfacine extended
RxNorm normalized name: Guanfacine Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanfacine extended release 2 mg/day
Trial: 18166547
Drug: Guanfacine extended
RxNorm normalized name: Guanfacine Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanfacine extended release 3 mg/day
Trial: 18166547
Drug: Guanfacine extended
RxNorm normalized name: Guanfacine Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanfacine extended release 4 mg/day
Trial: 18166547
Drug: Guanfacine extended
RxNorm normalized name: Guanfacine Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanfacine extended release (all doses)
Trial: 15923670
Drug: Peg-interferon alpha-2b
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peg-interferon alpha-2b (100 mug weekly) combined with daily lamivudine (100 mg)
Trial: 15923670
Drug: Peg-interferon alpha-2b
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peg-interferon alpha-2b (100 mug weekly) combined with placebo
Trial: 12952117
Drug: Azelastine nasal
RxNorm normalized name: azelastine nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelastine nasal spray 2 sprays per nostril, twice daily
Trial: 12952117
Drug: Azelastine nasal
RxNorm normalized name: azelastine nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelastine nasal spray plus loratadine 10 mg daily
Trial: 12952117
Drug: Desloratadine 5
RxNorm normalized name: desloratadine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desloratadine 5 mg daily plus placebo nasal spray
Trial: 10632736
Drug: Desmopressin after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin after aspirin treatment
Trial: 10632736
Drug: Desmopressin after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin after placebo treatment
Trial: 10632736
Drug: Second dose
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second dose of desmopressin
Trial: 9329702
Drug: Tacrine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrine with estrogen replacement therapy (ERT)
Trial: 9329702
Drug: Tacrine without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrine without estrogen replacement therapy (ERT)
Trial: 1622163
Drug: 2-day therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2-day therapy with rifampin (20 mg/kg of body weight per day, not to exceed 600 mg as a maximum single daily dose)
Trial: 1622163
Drug: 4-day therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-day therapy with rifampin (20 mg/kg of body weight per day, not to exceed 600 mg as a maximum single daily dose)
Trial: 28727629
Drug: Automated inpatient
RxNorm normalized name: Impatiens irvingii whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated inpatient split-dose bowel preparation system
Trial: 25439694
Drug: Radium-223 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radium-223 (50 kBq/kg intravenously, six injections, one every 4 weeks)
Trial: 22527350
Drug: Methantheline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methantheline (100 mg) as immediate-release coated tablets (IR)
Trial: 22527350
Drug: Methantheline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methantheline (100 mg) in watery solution (SOL)
Trial: 21309495
Drug: 2 ml
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml saline (placebo group)
Trial: 16243997
Drug: Clonidine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (2 microg/kg oral)
Trial: 7776458
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human tumor necrosis factor (200, 400, and 1,000 micrograms) given intravesically weekly for 11 weeks (dwell time 2 hours)
Trial: 2186066
Drug: PMR plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PMR plus cognitive therapy (PMR + Cog)
Trial: 378986
Drug: Lithium in
RxNorm normalized name: Product containing lithium in cutaneous dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium in combination with a thiazide diuretic
Trial: 378986
Drug: Lithium in
RxNorm normalized name: Product containing lithium in cutaneous dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium in combination with a low sodium diet
Trial: 28185444
Drug: Cis-palmitoleic acid
RxNorm normalized name: palmitoleic acid
DrugBank: Palmitoleic Acid (DB04257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cis-palmitoleic acid (720 mg/day for 8 weeks)
Trial: 21871373
Drug: Risperidone (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (mean dose 2.5 mg)
Trial: 21871373
Drug: Placebo (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (mean dose 3 mg)
Trial: 11561920
Drug: Midazolam injection
RxNorm normalized name: midazolam Injection
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam injection prior to study
Trial: 11561920
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no midazolam injection)
Trial: 8894146
Drug: 1.25 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg/day tibolone
Trial: 8894146
Drug: 2.5 mg/day
RxNorm normalized name: Androderm 2.5 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg/day tibolone
Trial: 1653141
Drug: Intranasal sumatriptan
RxNorm normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal sumatriptan (20 mg plus 20 mg)
Trial: 29519502
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg NGM282
Trial: 29519502
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg NGM282
Trial: 29519502
Drug: NGM282 (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NGM282 (both doses combined)
Trial: 27395805
Drug: Intensive ERP-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive ERP-based treatment (1 session psychoeducation, 2 sessions ERP plus e-therapy maintenance)
Trial: 16837737
Drug: Post-treatment
RxNorm normalized name: HYDROCORTISONE 1 g in 100 mL TOPICAL CREAM [Post-Treatment Repair Cream]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-treatment
Trial: 7593442
Drug: Long acting
RxNorm normalized name: Long Acting Nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long acting somatostatin analog (ST) 0.1 mg
Trial: 7593442
Drug: Long acting
RxNorm normalized name: Long Acting Nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long acting somatostatin analog (ST) 0.05 mg
Trial: 7593442
Drug: Long acting
RxNorm normalized name: Long Acting Nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long acting somatostatin analog (ST) 0.01 mg
Trial: 16553274
Drug: Control saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control saline injection
Trial: 30281074
Drug: Antimicrobial catheter
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial catheter lock solution containing trimethoprim 5 mg/mL, ethanol 25%, and Ca‐EDTA 3% (IMD)
Trial: 30281074
Drug: Heparin 5000
RxNorm normalized name: HEPARIN 5000 UNT/ML SYRINGE 1ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin 5000 U/mL (active control heparin, ACH)
Trial: 30281074
Drug: Antimicrobial catheter
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial catheter lock solution (IMD)
Trial: 30281074
Drug: Heparin 5000
RxNorm normalized name: HEPARIN 5000 UNT/ML SYRINGE 1ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin 5000 U/mL (ACH)
Trial: 29624592
Drug: Oral cholera
RxNorm normalized name: VIBRIO CHOLERAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cholera vaccine CVD 103-HgR (5 × 10^8 CFU)
Trial: 23885792
Drug: Azilsartan (20-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azilsartan (20-40 mg once daily)
Trial: 23885792
Drug: Candesartan (8-12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan (8-12 mg once daily)
Trial: 20550489
Drug: Preserved topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preserved topical levofloxacin (0.01% benzododecinium bromide)
Trial: 20550489
Drug: Unpreserved topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unpreserved topical levofloxacin
Trial: 17502775
Drug: Aripiprazole monotherapy
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole monotherapy (30 mg once daily) for 14 days
Trial: 2131900
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg of diphenhydramine 30 minutes prior to heparin administration (Group II)
Trial: 2131900
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg of cimetidine 4 hours and again 30 minutes before heparin administration (Group III)
Trial: 2131900
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg of diphenhydramine 30 minutes prior to heparin administration and 5 mg/kg of cimetidine 4 hours and 30 minutes before heparin administration (Group IV)
Trial: 2131900
Drug: No histamine-receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No histamine-receptor blockade (Group I - Control)
Trial: 23289899
Drug: NWP06 (extended-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NWP06 (extended-release methylphenidate)
Trial: 19239556
Drug: Rosmarinic acid
RxNorm normalized name: ROSMARINIC ACID
DrugBank: Rosmarinic acid (DB16865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosmarinic acid (0.3%) emulsion applied topically twice a day (morning and evening)
Trial: 15925737
Drug: Flavonoid-rich dark
RxNorm normalized name: dark leaved mugwort pollen extract
DrugBank: Artemisia ludoviciana pollen (DB10762)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavonoid-rich dark chocolate (100 g)
Trial: 12181083
Drug: huperzine Alpha
RxNorm normalized name: huperzine A
DrugBank: Huperzine A (DB04864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: huperzine Alpha 400 micro g/day for 12 weeks
Trial: 2016620
Drug: Intravenous human
RxNorm normalized name: botulism immune globulin IV human Injection [BabyBIG]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous human recombinant interferon beta (rIFN‐beta; Betaseron) given by IV infusion over 30 minutes 3 times per week (MWF) with dose escalation: 50-100-200, 100-200-400, 200-300-500, and 300-400-600 x 10(6) IU/m2.
Trial: 7326374
Drug: No continuity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No continuity of caregiver or special treatment (Group 4)
Trial: 21291943
Drug: Topiramate (100-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate (100-200 mg/day)
Trial: 18928481
Drug: Nesiritide (NES)
RxNorm normalized name: nesiritide
DrugBank: Nesiritide (DB04899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nesiritide (NES) 72-hour infusion at 0.01 mcg/kg/min
Trial: 16609069
Drug: Intrathecal triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal triple therapy (MTX, cytarabine, and hydrocortisone sodium succinate)
Trial: 8215479
Drug: Granisetron (3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron (3.0 mg/body) with methylprednisolone sodium (750 mg/body)
Trial: 8215479
Drug: Methylprednisolone sodium
RxNorm normalized name: methylPREDNISolone sodium phosphate
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone sodium (750 mg/body) plus metoclopramide (46.7 mg/body on average) and domperidone (82.9 mg/body on average)
Trial: 2485052
Drug: Lisinopril (LIS)
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lisinopril (LIS) 20-80 mg q.d., n = 10
Trial: 2485052
Drug: Nifedipine (NIF)
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine (NIF) 20-40 mg b.i.d., n = 5
Trial: 26842425
Drug: Structured, moderate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured, moderate intensity physical activity program (n=818) conducted in a center (twice a week) and at home (3‐4 times a week) including aerobic, strength, flexibility, and balance training activities.
Trial: 24504686
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine (0.5‐0.8 U/kg)
Trial: 24504686
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine (SC)
Trial: 15730350
Drug: Reserpine 0.5
RxNorm normalized name: reserpine 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reserpine 0.5 mg
Trial: 25218827
Drug: Gabapentin 1800
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin 1800 mg
Trial: 15730350
Drug: Lamotrigine 150
RxNorm normalized name: lamotrigine 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamotrigine 150 mg
Trial: 10756218
Drug: Nebulized budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nebulized budesonide 0.25 mg every 6 hours (group A)
Trial: 10756218
Drug: Nebulized ipratropium
RxNorm normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulized ipratropium bromide 0.1 mg every 6 hours (group B)
Trial: 9161235
Drug: Salmon calcitonin
RxNorm normalized name: Salmon calcitonin
DrugBank: Salmon calcitonin (DB00017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmon calcitonin (100 IU in 1 mL saline) administered three times per week for 3 weeks
Trial: 9161235
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 mL saline) administered three times per week for 3 weeks
Trial: 8339551
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg oral simvastatin daily for 2 years
Trial: 8339551
Drug: Placebo daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo daily for 2 years
Trial: 24120718
Drug: i.v. sugammadex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. sugammadex 4 mg/kg with oral aspirin 75 mg
Trial: 24120718
Drug: i.v. sugammadex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. sugammadex 4 mg/kg
Trial: 19344563
Drug: Sublingual ketorolac
RxNorm normalized name: ketorolac Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual ketorolac (30 mg, three doses)
Trial: 19344563
Drug: IV metamizole
RxNorm normalized name: Metamizole
DrugBank: Metamizole (DB04817)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV metamizole (1 g)
Trial: 9764063
Drug: Electrophysiologically guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrophysiologically guided treatment
Trial: 8141445
Drug: Flunitrazepam (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam (1.2 mg.h‐1) + Fentanyl (1.2 mg.h‐1)
Trial: 8141445
Drug: Isoflurane (0.6‐1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflurane (0.6‐1.2 vol%) + Fentanyl (1.2 mg.h‐1)
Trial: 8141445
Drug: Propofol (4‐8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (4‐8 mg.kg‐1.h‐1) + Fentanyl (1.2 mg.h‐1)
Trial: 3290709
Drug: Methylprednisolone and
RxNorm normalized name: methylprednisolone and antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone and Azathioprine combination therapy
Trial: 31021890
Drug: Split-dose preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split-dose preparation (4-L polyethylene glycol)
Trial: 31021890
Drug: Same-day preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same-day preparation (4-L polyethylene glycol)
Trial: 31021890
Drug: Bowel preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bowel preparation ≥7 hours before colonoscopy
Trial: 28219104
Drug: Captopril (3×50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (3×50 mg/day)
Trial: 23142441
Drug: Single-injection femoral
RxNorm normalized name: Sus scrofa temporal lobe preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-injection femoral nerve block (FNB)
Trial: 15910868
Drug: Molsidomine 16
RxNorm normalized name: molsidomine
DrugBank: Molsidomine (DB09282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Molsidomine 16 mg once a day (o.a.d.)
Trial: 8574301
Drug: Dehydrating medications
RxNorm normalized name: Dehydrated Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dehydrating medications
Trial: 2503020
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of 20 mg sodium cromoglycate
Trial: 367509
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg vancomycin six-hourly for five days
Trial: 27576774
Drug: Continued thienopyridine
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued thienopyridine therapy (75 to 325 mg aspirin daily)
Trial: 28297015
Drug: Continued thienopyridine
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued thienopyridine therapy
Trial: 24887576
Drug: Low-dose contrast
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose contrast medium (400 mgI/kg) with 80 kV(p)
Trial: 19707728
Drug: 6-h Evidence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-h Evidence Based Medicine (EBM) Workshop
Trial: 16168039
Drug: Psychotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotherapy and antidepressants
Trial: 10456592
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (ear acupuncture)
Trial: 1817903
Drug: Unknown anesthetic
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unknown anesthetic solutions
Trial: 6983500
Drug: Trimethoprim (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim (300 mg at night)
Trial: 6983500
Drug: Co-trimoxazole (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-trimoxazole (two tablets 12-hourly for seven days)
Trial: 31442001
Drug: Intraoperative antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative antibiotics prescribed by 95.0% of surgeons
Trial: 31442001
Drug: Postoperative antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative antibiotics prescribed by 73.6% of respondents
Trial: 31442001
Drug: Factors influencing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Factors influencing intraoperative antibiotic use
Trial: 31442001
Drug: Factors influencing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Factors influencing postoperative antibiotic use
Trial: 29085957
Drug: Immediate teriparatide
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Immediate teriparatide therapy
Trial: 29085957
Drug: Delayed teriparatide
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Delayed teriparatide therapy
Trial: 25567311
Drug: Cisplatin 100
RxNorm normalized name: CISPLATIN 100MG/VIL (PF) INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 100 mg/m² q3w (standard group)
Trial: 25567311
Drug: Cisplatin 80
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 80 mg/m² q3w (study group)
Trial: 25567311
Drug: Cisplatin 80
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 80 mg/m² q3w or 100 mg/m² q3w
Trial: 22765322
Drug: Medication management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication management augmented with emotionally focused therapy (MM + EFT)
Trial: 22765322
Drug: Medication management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication management alone (MM)
Trial: 18382805
Drug: BCG vaccine
RxNorm normalized name: BCG Vaccine
DrugBank: BCG vaccine (DB12768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG vaccine (1-3 doses with a one-month interval)